Advertisement

Topics

Osteoporosis Disease Management Demonstration Project

2014-08-27 03:51:54 | BioPortfolio

Summary

The purpose of the study is to evaluate the impact disease management interventions in treatment compliance among post-fracture and osteoporosis patients.

Study Design

Allocation: Randomized, Control: Placebo Control, Intervention Model: Parallel Assignment, Masking: Open Label

Conditions

Osteoporosis

Intervention

Disease Management Assessment

Status

Completed

Source

Merck

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:51:54-0400

Clinical Trials [1096 Associated Clinical Trials listed on BioPortfolio]

Osteoporosis Disease Management Demonstration Project (0000-037)

The purpose of this study is to assess the impact of disease management interventions on bone mineral density (BMD) screening rates and osteoporosis treatment rates in women age 65 years o...

Improving Management of Patients at High Risk for Osteoporotic Fractures

The purpose of this study is to assess the impact of disease management interventions on percent receiving a bone densitometry test and percent appropriately prescribed a medication for os...

Education for Osteoporosis in Persons With Existing Fractures

We wish to investigate whether a weekly, 2½ hour group-based osteoporosis education intervention (the Osteoporosis Prevention and Self-Management Course), is different to one session cour...

Clinical Value of Self-assessment Risk of Osteoporosis in Chinese

This cross-sectional study aimed to validate the effectiveness of the combined use of the Osteoporosis Self-Assessment Tool for Asians (OSTA) and the One-Minute Osteoporosis Risk Test (IOF...

Osteoporosis and Chronic Obstructive Pulmonary Disease (COPD)

The goals of the trial are: - To determine the prevalence of osteoporosis in subgroups of COPD patients. - To look for risk factors of osteoporosis in COPD patients. - To...

PubMed Articles [26169 Associated PubMed Articles listed on BioPortfolio]

Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.

In renal transplant patients, bone loss may be related to the drugs patients are taking but also to their past history of chronic kidney disease. The purpose of this study was to assess changes in BMD...

EAA clinical guideline on management of bone health in the andrological outpatient clinic.

Male osteoporosis is now a well-recognized medical disorder with established clinical guidelines for both diagnosis and management. Prevention as well as management of osteoporosis in men consulting t...

Management of osteoporosis after fragility fractures.

Osteoporosis is defined as a systemic bone disease with decreased bone strength and an increased susceptibility for fractures. Older people in particular face an increased risk of fractures. These ki...

Portuguese recommendations for the prevention, diagnosis and management of primary osteoporosis - 2018 update.

Advances in osteoporosis (OP)case definition, treatment options, optimal therapy duration and pharmacoeconomic evidence in the national context motivated the Portuguese Society of Rheumatology (SPR) t...

Assessing the associations of blood metabolites with osteoporosis: a Mendelian randomization study.

Osteoporosis is a metabolic bone disease. The impact of blood metabolites on the development of osteoporosis remains elusive now.

Medical and Biotech [MESH] Definitions

Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.

A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

An early onset form of phytanic acid storage disease with clinical and biochemical signs different from those of REFSUM DISEASE. Features include MENTAL RETARDATION; SENSORINEURAL HEARING LOSS; OSTEOPOROSIS; and severe liver damage. It can be caused by mutation in a number of genes encoding proteins involving in the biogenesis or assembly of PEROXISOMES.

Participation of employees with management as a labor-management team, in decisions pertaining to the operational activities of the organization or industry.

More From BioPortfolio on "Osteoporosis Disease Management Demonstration Project"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...


Searches Linking to this Trial